Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Corline Biomedical

9.86

 

SEK

 

-2.86 %

Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
241.48M SEK
Turnover
194.47K SEK
Revenue
9.78M
EBIT %
-236.91 %
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2025

Interim report Q2'25

11/11
2025

Interim report Q3'25

17/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Regulatory press release5/15/2025, 9:00 AM

Kommuniké från årsstämma i Corline Biomedical AB (publ)

Corline Biomedical
Press release5/14/2025, 9:44 AM

Analyst Group: Analyst Group intervjuar Corline Biomedicals VD Henrik Nittmar

Corline Biomedical
Press release5/11/2025, 3:51 PM

Redeye: Corline Biomedical Q1 - Exciting quarters ahead

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/8/2025, 6:45 AM

Corline Biomedical AB offentliggör delårsrapport för perioden januari till mars 2025

Corline Biomedical
Press release4/26/2025, 11:27 AM

Kardium redovisar starka ettårsresultat och hög säkerhet i PULSAR-IDE-studien

Corline Biomedical
Regulatory press release4/24/2025, 1:35 PM

Corline Biomedical publicerar årsredovisning för 2024

Corline Biomedical
Regulatory press release4/9/2025, 2:41 PM

KALLELSE TILL ÅRSSTÄMMA I CORLINE BIOMEDICAL AB

Corline Biomedical
Press release2/18/2025, 7:34 AM

Redeye: Corline Biomedical Q4 - Focus on Kardium’s market launch

Corline Biomedical
Regulatory press release2/17/2025, 7:45 AM

Corline Biomedical AB offentliggör bokslutskommuniké för perioden januari till december 2024

Corline Biomedical
Press release2/4/2025, 6:47 AM

Redeye: Redeye Initiates Coverage of Corline Biomedical

Corline Biomedical
Press release12/23/2024, 7:56 AM

Corlines kund Kardium meddelar att man lämnat in ansökan om godkännande till FDA

Corline Biomedical
Regulatory press release11/20/2024, 11:14 AM

Corline Biomedical AB omförhandlar avtal med Imperative Care för att bredda kundbearbetningen inom neurovaskulära CHS™-applikationer

Corline Biomedical
Regulatory press release11/19/2024, 3:17 PM

Corline Biomedical AB offentliggör utfall av riktad emission av aktier

Corline Biomedical
Press release11/11/2024, 2:56 PM

Penser Access & Future by Carnegie: Corline Biomedical: Intervju – Fullt fokus på medicinteknik

Corline Biomedical
Press release11/8/2024, 8:01 AM

Penser Access & Future by Carnegie: Corline Biomedical: Med fokus på medicinteknik - Q3 review

Corline Biomedical
Regulatory press release11/7/2024, 7:45 AM

Corline Biomedical AB offentliggör delårsrapport för perioden januari till september 2024

Corline Biomedical
Regulatory press release11/7/2024, 7:20 AM

Corline Biomedical genomför en riktad emission om 18 MSEK

Corline Biomedical
Press release10/25/2024, 7:27 AM

Corline Biomedical uppdaterar hemsida i samband med strategiuppdateringen

Corline Biomedical
Press release10/24/2024, 10:49 AM

Marknadsaktörer spår att snabbväxande PFA-segment kommer ta mer än 60 % av marknaden för hjärtflimmerbehandling redan 2026

Corline Biomedical
Regulatory press release9/12/2024, 6:40 AM

Corline Biomedical AB uppdaterar sin strategiska plan för att accelerera vägen fram till lönsamhet och höjer framtida försäljningspotential

Corline Biomedical
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team